A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
Condition: Breast Cancer Interventions: Drug: Ipatasertib; Drug: Placebo; Drug: Palbociclib; Drug: Fulvestrant Sponsor: Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials